New drug trial seeks to control aggressive breast cancer

NCT ID NCT07311993

First seen Jan 06, 2026 · Last updated Apr 16, 2026 · Updated 13 times

Summary

This early-stage study is testing three different dose levels of an experimental drug called CLR 125 in people with advanced triple-negative breast cancer that has returned or stopped responding to other treatments. The main goals are to find the safest and most effective dose for future studies and to understand what side effects patients experience. About 60 participants will receive the drug through an IV infusion every 8 weeks and be closely monitored.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Mayo Clinic Florida

    NOT_YET_RECRUITING

    Jacksonville, Florida, 32224, United States

    Contact

  • United Theranostics

    RECRUITING

    Glen Burnie, Maryland, 21061, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • United Theranostics

    RECRUITING

    Princeton, New Jersey, 08540, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.